CN103313711A - 在纳曲酮疗法中增加药物生物可利用性 - Google Patents

在纳曲酮疗法中增加药物生物可利用性 Download PDF

Info

Publication number
CN103313711A
CN103313711A CN2011800638854A CN201180063885A CN103313711A CN 103313711 A CN103313711 A CN 103313711A CN 2011800638854 A CN2011800638854 A CN 2011800638854A CN 201180063885 A CN201180063885 A CN 201180063885A CN 103313711 A CN103313711 A CN 103313711A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
naltrexone
amfebutamone
food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800638854A
Other languages
English (en)
Chinese (zh)
Inventor
肖恩·弗拉纳根
艾杜阿尔多·度纳耶维奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orexigen Therapeutics Inc
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103313711(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of CN103313711A publication Critical patent/CN103313711A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acoustics & Sound (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
CN2011800638854A 2010-12-03 2011-12-02 在纳曲酮疗法中增加药物生物可利用性 Pending CN103313711A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41939510P 2010-12-03 2010-12-03
US61/419,395 2010-12-03
PCT/US2011/063177 WO2012075459A1 (en) 2010-12-03 2011-12-02 Increasing drug bioavailability in naltrexone therapy

Publications (1)

Publication Number Publication Date
CN103313711A true CN103313711A (zh) 2013-09-18

Family

ID=46172304

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800638854A Pending CN103313711A (zh) 2010-12-03 2011-12-02 在纳曲酮疗法中增加药物生物可利用性

Country Status (27)

Country Link
US (1) US20130245056A1 (https=)
EP (5) EP4696322A3 (https=)
JP (5) JP6008866B2 (https=)
KR (5) KR20140035320A (https=)
CN (1) CN103313711A (https=)
AR (2) AR093182A1 (https=)
AU (2) AU2011336304B2 (https=)
BR (1) BR112013013390A2 (https=)
CA (2) CA2819262C (https=)
CL (1) CL2013001564A1 (https=)
CY (2) CY1118968T1 (https=)
DK (4) DK3222280T3 (https=)
ES (3) ES2866879T3 (https=)
FI (2) FI3884947T3 (https=)
HR (4) HRP20251576T1 (https=)
HU (3) HUE053831T2 (https=)
IL (3) IL226504B (https=)
LT (4) LT4349369T (https=)
MX (2) MX356801B (https=)
PL (4) PL3884947T3 (https=)
PT (4) PT3884947T (https=)
RS (4) RS56014B1 (https=)
RU (1) RU2640561C2 (https=)
SI (4) SI3222280T1 (https=)
SM (4) SMT201700232T1 (https=)
TW (1) TWI618536B (https=)
WO (1) WO2012075459A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111050801A (zh) * 2017-03-28 2020-04-21 Ldn制药有限公司 用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034290T2 (en) 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
SMT201700232T1 (it) * 2010-12-03 2017-07-18 Orexigen Therapeutics Inc Aumento della biodisponibilita' farmacologica nella terapia con naltrexone
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
US20180015042A1 (en) * 2015-02-07 2018-01-18 Intas Pharmaceuticals Ltd. Pharmaceutical composition for the treatment of obesity
EP3482751A1 (en) 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101588795A (zh) * 2006-11-09 2009-11-25 奥雷西根治疗公司 包含中间快速溶解层的分层药物制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
EP1772147A2 (en) * 2003-03-17 2007-04-11 Japan Tobacco, Inc. Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
HUE034290T2 (en) 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss
US20070117827A1 (en) 2005-07-27 2007-05-24 Gary Tollefson Compositions for affecting weight loss
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
JP2009517393A (ja) 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
SI2719378T1 (sl) * 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
KR101264789B1 (ko) 2006-06-30 2013-05-15 엘지디스플레이 주식회사 횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법
CA2693992C (en) * 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
LT2545939T (lt) * 2007-04-11 2021-03-10 Biomarin Pharmaceutical Inc. Tetrahidrobiopterinas, skirtas gydyti ligas, susijusias supadidėjusiu fenilalanino kiekiu
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
US8318813B2 (en) * 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
SMT201700232T1 (it) 2010-12-03 2017-07-18 Orexigen Therapeutics Inc Aumento della biodisponibilita' farmacologica nella terapia con naltrexone

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101588795A (zh) * 2006-11-09 2009-11-25 奥雷西根治疗公司 包含中间快速溶解层的分层药物制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111050801A (zh) * 2017-03-28 2020-04-21 Ldn制药有限公司 用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂

Also Published As

Publication number Publication date
CA3239386A1 (en) 2012-06-07
ES3056642T3 (en) 2026-02-23
JP2019056004A (ja) 2019-04-11
AR093182A1 (es) 2015-05-27
KR101984500B1 (ko) 2019-05-31
AU2011336304A1 (en) 2013-07-11
HUE034393T2 (en) 2018-02-28
MX2013006071A (es) 2013-10-01
TW201304780A (zh) 2013-02-01
RS65198B1 (sr) 2024-03-29
EP2646031A4 (en) 2014-04-23
KR20200044158A (ko) 2020-04-28
EP4349369A2 (en) 2024-04-10
EP4696322A2 (en) 2026-02-18
EP4349369B1 (en) 2025-09-17
RU2640561C2 (ru) 2018-01-09
HRP20240115T1 (hr) 2024-06-07
JP2013544290A (ja) 2013-12-12
SMT202400038T1 (it) 2024-03-13
EP3884947B1 (en) 2023-11-15
IL226504B (en) 2021-01-31
RS67527B1 (sr) 2026-01-30
LT3884947T (lt) 2024-03-12
RU2017144631A (ru) 2019-02-18
TWI618536B (zh) 2018-03-21
SMT202500474T1 (it) 2026-01-12
HUE053831T2 (hu) 2021-07-28
HUE065852T2 (hu) 2024-06-28
AU2011336304B2 (en) 2017-03-30
CY1124331T1 (el) 2022-07-22
RS62149B1 (sr) 2021-08-31
DK4349369T3 (da) 2025-12-22
PL3884947T3 (pl) 2024-05-06
RU2017144631A3 (https=) 2021-04-13
AU2017204309A1 (en) 2017-07-13
PL3222280T3 (pl) 2021-11-29
ES2866879T3 (es) 2021-10-20
FI3884947T3 (fi) 2024-01-30
EP4349369A3 (en) 2024-05-15
KR20180069089A (ko) 2018-06-22
DK3222280T3 (da) 2021-04-19
SI3222280T1 (sl) 2021-11-30
MX356801B (es) 2018-06-13
JP7025319B2 (ja) 2022-02-24
CY1118968T1 (el) 2018-01-10
KR102105857B1 (ko) 2020-05-04
BR112013013390A2 (pt) 2016-09-06
CA2819262A1 (en) 2012-06-07
CA2819262C (en) 2024-05-28
RU2013127423A (ru) 2015-01-10
DK2646031T3 (en) 2017-05-22
AR124500A2 (es) 2023-04-05
MX384662B (es) 2025-03-14
SI2646031T1 (sl) 2017-07-31
WO2012075459A1 (en) 2012-06-07
PT3222280T (pt) 2021-04-22
DK3884947T3 (da) 2024-01-22
EP2646031B1 (en) 2017-02-22
LT4349369T (lt) 2026-01-12
EP2646031B9 (en) 2018-01-10
JP2024071605A (ja) 2024-05-24
ES2625527T9 (es) 2018-09-25
EP2646031A1 (en) 2013-10-09
EP4696322A3 (en) 2026-04-15
PL2646031T3 (pl) 2017-08-31
RS56014B1 (sr) 2017-09-29
KR20140035320A (ko) 2014-03-21
IL279626A (en) 2021-03-01
EP3222280A1 (en) 2017-09-27
US20130245056A1 (en) 2013-09-19
PT2646031T (pt) 2017-05-25
KR20210063473A (ko) 2021-06-01
HRP20210618T1 (hr) 2021-09-17
HRP20170734T1 (hr) 2017-08-11
ES2625527T3 (es) 2017-07-19
JP2022060331A (ja) 2022-04-14
EP3884947A1 (en) 2021-09-29
LT3222280T (lt) 2021-05-10
PT4349369T (pt) 2025-12-17
FI4349369T3 (fi) 2025-12-17
IL270841A (en) 2020-01-30
SI3884947T1 (sl) 2024-06-28
SMT201700232T1 (it) 2017-07-18
PT3884947T (pt) 2024-02-16
JP6008866B2 (ja) 2016-10-19
JP6456890B2 (ja) 2019-01-23
EP3222280B1 (en) 2021-01-20
HRP20251576T1 (hr) 2026-01-30
KR102258043B1 (ko) 2021-05-28
KR102391511B1 (ko) 2022-04-26
JP2016210809A (ja) 2016-12-15
SI4349369T1 (sl) 2026-02-27
KR20190058702A (ko) 2019-05-29
LT2646031T (lt) 2017-06-26
SMT202100227T1 (it) 2021-07-12
CL2013001564A1 (es) 2014-05-02
PL4349369T3 (pl) 2026-03-23

Similar Documents

Publication Publication Date Title
JP7025319B2 (ja) ナルトレキソン療法における薬物バイオアベイラビリティの増加
US20220233520A1 (en) Increasing Drug Bioavailability In Naltrexone Therapy
RU2781141C2 (ru) Повышение биодоступности лекарственных средств при терапии налтрексоном
HK1188136B (en) Increasing drug bioavailability in naltrexone therapy
HK1188136A (en) Increasing drug bioavailability in naltrexone therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20130918

RJ01 Rejection of invention patent application after publication